Muscle News and Research

RSS

UK MRC, Humabs discover first neutralizing antibody that targets all influenza A subtypes

A paper published today in the scientific research journal Science, describes a novel, proprietary monoclonal antibody (FI6) discovered in a collaboration between Humabs BioMed SA, the Institute for Research in Biomedicine and the UK Medical Research Council.

29 Jul 2011

Muscle mass may influence risk for diabetes: Study

According to a new study greater muscle mass may reduce the odds of developing diabetes. There have been studies that show having less body fat reduces diabetes risk and that exercise can help too, but the new study by UCLA scientists suggests a link between higher muscle mass and a lower risk of diabetes.

29 Jul 2011

Curis second quarter net loss increases to $4.9 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2011.

28 Jul 2011

Relative muscle mass inversely linked with insulin resistance and pre-diabetes

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that the greater an individual's total muscle mass, the lower the person's risk of having insulin resistance, the major precursor of type 2 diabetes.

28 Jul 2011

Yoga reduces symptoms of chronic pain in women with fibromyalgia

A new study by York University researchers finds that practicing yoga reduces the physical and psychological symptoms of chronic pain in women with fibromyalgia.

28 Jul 2011

New LEAP technique can restore heart rhythm in patients with atrial fibrillation

A high-amplitude, and often painful, electrical shock is the only currently available method for treating certain cases of chronic cardiac arrhythmia. But now a new technique using much weaker impulses has been developed by an international team of physicists and cardiologists, including Alain Pumir, CNRS researcher at the ENS Lyon physics laboratory.

28 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Underwater-treadmill improves mobility following spinal-cord injury

The result of research often is shown in hard and fast metrics. For Janette Rodgers, the only metric she cares about is that her wheelchair, once her prison day in and day out, now sits empty 90 percent of the time— in large part because of the hours she spent in 270 gallons of water.

27 Jul 2011

Positive results from phase Ib/IIa trial of novel molecular technique for Duchenne muscular dystrophy

A molecular technique originally developed at the University of North Carolina at Chapel Hill has taken one step closer to becoming a treatment for the devastating genetic disease Duchenne muscular dystrophy.

27 Jul 2011

High-dose vitamin D reduces musculoskeletal pain in breast cancer patients

High-dose vitamin D relieves joint and muscle pain for many breast cancer patients taking estrogen-lowering drugs, according to a new study from Washington University School of Medicine in St. Louis.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Key risk factors for death, transplantation in children with dilated cardiomyopathy

Researchers have identified important risk factors for death and transplantation in children with dilated cardiomyopathy, according to results from a study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

26 Jul 2011

Symposium papers highlight role of oxidative stress in cardiovascular disease

Recent years have seen major advances in understanding of the health effects of oxidative stress—including its potential to cause injury to the cardiovascular system. A series of expert updates on the role of oxidative stress in heart failure, atherosclerosis, and other cardiovascular diseases appears in a special symposium in the August issue of The American Journal of the Medical Sciences, official journal of the Southern Society for Clinical Investigation.

26 Jul 2011

New hope for infants born with Spinal Muscular Atrophy

Researchers in Ottawa report new hope for the treatment of infants born with serious genetic disorder.

26 Jul 2011

Fragile X syndrome study to reveal more

Fragile X syndrome is the most common inherited cause of intellectual disability in the world. Medical experts, including the Mater Hospital's Dr Helen Heussler, are today launching a new push to uncover the secrets of a disorder that affects a child born in Australia every week. Fragile X is passed from parent carriers who often exhibit very few symptoms. Estimates suggest more than 100,000 Australians either carry the gene mutation that causes Fragile X or have the syndrome, yet the vast majority have not been diagnosed, according to the Fragile X Association of Australia.

25 Jul 2011

Promising drug for Duchenne muscular dystrophy

Duchenne muscular dystrophy is a severely debilitating and lethal condition that affects 1 in 3,000. Females and males are affected, though females are rarely affected and are more often carriers. It is caused due to a defective gene that normally codes for the protein dystrophin, which helps provide a protective membrane around muscle fibers. Without this skin, muscle fibers become damaged and eventually die.

25 Jul 2011

Illinois Bone and Joint Institute upgrades to High Field Open MRI System

Illinois Bone and Joint Institute, MRI Services, is proud to announce the installation of the first High Field Open MRI serving patients of Chicago and Northeastern Illinois.

25 Jul 2011

Janssen receives FDA Complete Response letter for SIMPONI sBLA to treat RA

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI.

25 Jul 2011